利用治疗药物监测指导头孢他啶/阿维巴坦治疗产KPC的中枢神经系统感染
Using Therapeutic Drug Monitoring to Treat KPC-Producing Central Nervous System Infection With Ceftazidime/Avibactam.
作者信息
Yasmin Mohamad, Hanrahan Jennifer, Marshall Steven, Lodise Thomas P, Chen Liang, Perez Federico, Kreiswirth Barry, Bonomo Robert A
机构信息
Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Division of Infectious Diseases, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
出版信息
Open Forum Infect Dis. 2020 Aug 18;7(9):ofaa349. doi: 10.1093/ofid/ofaa349. eCollection 2020 Sep.
This report describes the treatment of carbapenemase (KPC)-3-producing multidrug-resistant with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC- central nervous system infections.
本报告描述了一名发生神经外科术后脑膜炎和菌血症的产碳青霉烯酶（KPC）-3多重耐药患者使用头孢他啶/阿维巴坦（CAZ-AVI）的治疗情况。对脑脊液和血液样本进行的治疗药物监测显示，输注后最初60分钟内CAZ-AVI浓度水平比最低抑菌浓度高20倍，这为CAZ-AVI治疗KPC中枢神经系统感染的效用提供了证据。
Zotero 插件